Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 2/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.32 |
| ▸ | MGLL | Q99685 | 2/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | TSSK1B | Q9BXA7 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2488149 | 0.87 | AURKA (0.48) | AURKAAURKBCHEK1SRCCDK2 | |
| SCHEMBL2513543 | 0.86 | AURKA (0.50) | AURKAAURKBCHEK1SRCCDK2 | |
| SCHEMBL2489263 | 0.84 | AURKA (0.48) | AURKAAURKBCHEK1SRCCDK2 | |
| SCHEMBL2486921 | 0.84 | AURKA (0.48) | AURKAAURKBCHEK1SRCCDK2 | |
| SCHEMBL2485583 | 0.84 | AURKA (0.48) | AURKAAURKBCHEK1SRCCDK2 | |
| SCHEMBL13341289 | 0.84 | AURKA (0.52) | AURKAAURKBKMT2AMEN1TP53 | |
| SCHEMBL13341292 | 0.83 | AURKA (0.50) | AURKAAURKBKDRKMT2AMEN1 | |
| SCHEMBL2492668 | 0.83 | AURKA (0.47) | AURKAAURKBCHEK1SRCCDK2 | |
| SCHEMBL13368132 | 0.82 | AURKA (0.53) | AURKAAURKBSCN9ATP53MAPT | |
| SCHEMBL3429042 | 0.81 | AURKA (0.46) | AURKAAURKBCHEK1SRCCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756112-B1 | PYRROLOBENZIMIDAZOLONES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | BOEHRINGER INGELHEIM INT (DE) | 2011-10-26 | — | — | EP | disclosed |
| US-7714010-B2 | Pyrrolobenzimidazolones and their use as anti-proliferative agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-11 | — | — | US | disclosed |
| US-7714010-B2 | Pyrrolobenzimidazolones and their use as anti-proliferative agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-11 | — | — | US | disclosed |
| US-7714010-B2 | Pyrrolobenzimidazolones and their use as anti-proliferative agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-11 | — | — | US | disclosed |
| US-20050261350-A1 | Pyrrolobenzimidazolones and their use as anti-proliferative agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-24 | — | — | US | disclosed |
| EP-1598353-A1 | Pyrrolobenzimidazolones and their use as antiproliferative agents | Boehringer Ingelheim International GmbH (DE) | 2005-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261350-A1 | Pyrrolobenzimidazolones and their use as anti-proliferative agents | MKI67, CCNI, CCNA1 | AURKA 268/4885AURKB 215/4885CHEK1 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.